193 related articles for article (PubMed ID: 8405016)
1. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects.
Pue MA; Laroche J; Meineke I; de Mey C
Eur J Clin Pharmacol; 1993; 44(6):575-8. PubMed ID: 8405016
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of pantoprazole in man.
Huber R; Hartmann M; Bliesath H; Lühmann R; Steinijans VW; Zech K
Int J Clin Pharmacol Ther; 1996 May; 34(5):185-94. PubMed ID: 8738854
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and tolerance of pantoprazole, a proton pump inhibitor after single and multiple oral doses in healthy Japanese volunteers.
Tanaka M; Yamazaki H; Ryokawa Y; Hakusui H; Nakamichi N; Sekino H
Int J Clin Pharmacol Ther; 1996 Oct; 34(10):415-9. PubMed ID: 8897077
[TBL] [Abstract][Full Text] [Related]
4. Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration.
Bliesath H; Huber R; Hartmann M; Lühmann R; Wurst W
Int J Clin Pharmacol Ther; 1994 Jan; 32(1):44-50. PubMed ID: 8199751
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of pantoprazole in man.
Huber R; Hartmann M; Bliesath H; Lühmann R; Steinijans VW; Zech K
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S7-16. PubMed ID: 8793599
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Ishizaki T
Clin Pharmacol Ther; 2001 Mar; 69(3):108-13. PubMed ID: 11240974
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics--a relevant factor for the choice of a drug?
Benet LZ; Zech K
Aliment Pharmacol Ther; 1994; 8 Suppl 1():25-32. PubMed ID: 8180291
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet.
Ley LM; Stahlheber-Dilg B; Sander P; Huber R; Mascher H; Lücker PW
Methods Find Exp Clin Pharmacol; 2001; 23(1):41-5. PubMed ID: 11413863
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of pantoprazole in clinically normal neonatal foals.
Ryan CA; Sanchez LC; Giguère S; Vickroy T
Equine Vet J; 2005 Jul; 37(4):336-41. PubMed ID: 16028623
[TBL] [Abstract][Full Text] [Related]
11. Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution.
Ferron GM; Ku S; Abell M; Unruh M; Getsy J; Mayer PR; Paul J
Am J Health Syst Pharm; 2003 Jul; 60(13):1324-9. PubMed ID: 12901033
[TBL] [Abstract][Full Text] [Related]
12. Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration.
Bliesath H; Huber R; Hartmann M; Lühmann R; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S18-24. PubMed ID: 8793600
[TBL] [Abstract][Full Text] [Related]
13. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
Metz DC; Amer F; Hunt B; Vakily M; Kukulka MJ; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):985-95. PubMed ID: 16573801
[TBL] [Abstract][Full Text] [Related]
14. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.
Schulz HU; Hartmann M; Steinijans VW; Huber R; Lührmann B; Bliesath H; Wurst W
Int J Clin Pharmacol Ther Toxicol; 1991 Sep; 29(9):369-75. PubMed ID: 1834592
[TBL] [Abstract][Full Text] [Related]
15. Excretion of pantoprazole in human breast.
Plante L; Ferron GM; Unruh M; Mayer PR
J Reprod Med; 2004 Oct; 49(10):825-7. PubMed ID: 15568407
[TBL] [Abstract][Full Text] [Related]
16. Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole--a preliminary study.
Tanaka M; Yamazaki H; Hakusui H; Nakamichi N; Sekino H
Chirality; 1997; 9(1):17-21. PubMed ID: 9094198
[TBL] [Abstract][Full Text] [Related]
17. Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man.
Simon B; Müller P; Bliesath H; Lühmann R; Hartmann M; Huber R; Wurst W
Aliment Pharmacol Ther; 1990 Jun; 4(3):239-45. PubMed ID: 1966542
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats.
Ferron GM; McKeand W; Mayer PR
J Clin Pharmacol; 2001 Feb; 41(2):149-56. PubMed ID: 11210394
[TBL] [Abstract][Full Text] [Related]
19. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction.
De Mey C; Meineke I; Steinijans VW; Huber R; Hartmann M; Bliesath H; Wurst W
Int J Clin Pharmacol Ther; 1994 Feb; 32(2):98-106. PubMed ID: 8004366
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects.
Setoyama T; Laurent A; Humphries T; Hasegawa J
Int J Clin Pharmacol Ther; 2005 Jan; 43(1):37-42. PubMed ID: 15704613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
